Vanderbilt University School of Medicine

Carbone, David P. , M.D., Ph.D.

Lab Url: N/A

Phone Number: 615-936-3321


Carbone, David's picture

Office Address   Mailing Address

685 PRB

685 PRB Vanderbilt-Ingram Comprehensive Cancer Center 37232-6838

Research Keywords
Lung Cancer,Cancer,Chromosome,Gene regulation,Gene therapy,Genetics,Genomics,Human Genetics,Immunology,Malignancy,Mass spectroscopy,Molecular medicine,Mouse,Proteomics,Stem cells

Research Description
Our laboratory is interested in the molecular genetics of human solid tumors, and translation of these findings to therapy.

We approach this problem in several ways. One research direction of ours is the study of antitumor immune responses and overcoming tumor associated immunosuppression. Tumorigenesis appears to be associated with the appearance of mutant oncoprotein products, and we have been interested in whether these novel sequences are recognized by the cellular immune system, and how tumors avoid effective host responses to them. We discovered that a small proportion of lung cancer patients spontaneously develop antibody responses to p53, and that mutant p53-specific cytotoxic T cells can be induced in animals by peptide or genetic immunization. We have also demonstrated that tumors acquire the ability to "hide" these neoantigens either by somatically altering their ability to "present" them or by inhibiting the ability of the host to respond to them. We were the first to describe an acquired defect in the transport of intracellular peptide antigens to the cell surface due to a mutation in the TAP1 transporter protein. We also characterized mutations in b-2 microglobulin in lung and breast cancer, which also result in an acquired loss of antigen presentation. Interestingly, these cases appear to be the exception, and most human solid tumors can present endogenous mutant oncoprotein antigens. These data imply that the lack of an effective immune response may not be lack of antigenicity, but rather lack of immunogenicity, and we have turned our attention to characterizing the mechanism of this effect and methods to overcome it.

Our laboratory was the first to report that a major cause of the lack of host responses to tumor antigens is a tumor-associated defect in the host "professional antigen presenting cell" or dendritic cells. Further, we have discovered that vascular endothelial growth factor (VEGF), a molecule produced by most tumors and responsible for the induction of tumor neovasculature, also appears to have a selective inhibitory effect on the ability of bone marrow precursors to differentiate into functional dendritic cells. We have recently been using genetically modified embryonic stem cells to clarify this pathway of differentiation. We are initiating clinical trials to test this hypothesis in humans.

Another direction is to define clinically relevant molecular signatures of lung cancer through microarray and proteomics studies. Specifically, we are looking at both serum and tumor proteomic profiling and have defined profiles capable of histologic classification, prognostication, and prediction of response to therapy. These are being validated in large clinical trials and the proteins making up these signatures identified.

I have recently received funding for establishment of a "Specialized Program of Research Excellence" or SPORE in Lung Cancer. This effort involves multiple investigators with a wide range of research interests all focused on outstanding translational research in lung cancer.

In summary, our current laboratory goals are:

1) To better characterize the mechanisms involved in the observed cancer-associated dendritic cell functional defects, especially the receptors and the signal transduction pathway induced in hematopoeitic stem cells after exposure to VEGF, and the roles of specific prostaglandin receptors in immune response as well as tumor behavior.

2) To utilize cDNA microarrays and mass spectrometry to develop molecular signatures of lung cancers that might help predict their clinical behavior and response to therapy as well as identify potential new molecular targets.

Clinical Research Description
I am interested in novel lung cancer therapeutics, including small molecules, gene therapy, and immunotherapy.

Amann, JM, Lee, JW, Roder, H, Brahmer, J, Gonzalez, A, Schiller, JH, Carbone, DP. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol, 5(2), 169-78, 2010.

Chung, CH, Seeley, EH, Roder, H, Grigorieva, J, Tsypin, M, Roder, J, Burtness, BA, Argiris, A, Forastiere, AA, Gilbert, J, Murphy, B, Caprioli, RM, Carbone, DP, Cohen, EE. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev, 19(2), 358-65, 2010.

Konishi, J, Yi, F, Chen, X, Vo, H, Carbone, DP, Dang, TP. Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene, 29(4), 589-96, 2010.

Lin, L, Mernaugh, R, Yi, F, Blum, D, Carbone, DP, Dang, TP. Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res, 70(2), 632-8, 2010.

Carbone, DP. Profiles in variation: lung carcinogenesis. Cancer Prev Res (Phila Pa), 2(8), 695-7, 2009.

Carbone, DP, Salmon, JS, Billheimer, D, Chen, H, Sandler, A, Roder, H, Roder, J, Tsypin, M, Herbst, RS, Tsao, AS, Tran, HT, Dang, TP. VeriStrat((R)) classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer, , , 2009.

Moretti, L, Yu, DS, Chen, H, Carbone, DP, Johnson, DH, Keedy, VL, Putnam, JB, Sandler, AB, Shyr, Y, Lu, B. Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. Oncologist, 14(11), 1106-15, 2009.

Mutter, R, Lu, B, Carbone, DP, Csiki, I, Moretti, L, Johnson, DH, Morrow, JD, Sandler, AB, Shyr, Y, Ye, F, Choy, H. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res, 15(6), 2158-65, 2009.

Pao, W, Kris, MG, Iafrate, AJ, Ladanyi, M, J??nne, PA, Wistuba, II, Miake-Lye, R, Herbst, RS, Carbone, DP, Johnson, BE, Lynch, TJ. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res, 15(17), 5317-22, 2009.

Keedy, V, Wang, W, Schiller, J, Chada, S, Slovis, B, Coffee, K, Worrell, J, Thet, LA, Johnson, DH, Carbone, DP. Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597. J Clin Oncol, 26(25), 4166-71, 2008. PMCID:2654378

Novitskiy, SV, Ryzhov, S, Zaynagetdinov, R, Goldstein, AE, Huang, Y, Tikhomirov, OY, Blackburn, MR, Biaggioni, I, Carbone, DP, Feoktistov, I, Dikov, MM. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood, 112(5), 1822-31, 2008. PMCID:2518889

Ryzhov, S, Novitskiy, SV, Zaynagetdinov, R, Goldstein, AE, Carbone, DP, Biaggioni, I, Dikov, MM, Feoktistov, I. Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia, 10(9), 987-95, 2008. PMCID:2517644

Yang, L, Huang, J, Ren, X, Gorska, AE, Chytil, A, Aakre, M, Carbone, DP, Matrisian, LM, Richmond, A, Lin, PC, Moses, HL. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell, 13(1), 23-35, 2008. PMCID:2245859

Albert, JM, Gonzalez, A, Massion, PP, Chen, H, Olson, SJ, Shyr, Y, Diaz, R, Lambright, ES, Sandler, A, Carbone, DP, Putnam, JB, Johnson, DH, Lu, B. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev, 16(9), 1845-51, 2007. PMCID:2245859

Chung, CH, Levy, S, Chaurand, P, Carbone, DP. Genomics and proteomics: emerging technologies in clinical cancer research. Crit Rev Oncol Hematol, 61(1), 1-25, 2007.

Huang, Y, Chen, X, Dikov, MM, Novitskiy, SV, Mosse, CA, Yang, L, Carbone, DP. Distinct roles of VEGFR-1 and -2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood, , , 2007. PMCID:1924481

Kikuchi, T, Carbone, DP. Proteomics analysis in lung cancer: challenges and opportunities. Respirology, 12(1), 22-8, 2007.

Konishi, J, Kawaguchi, KS, Vo, H, Haruki, N, Gonzalez, A, Carbone, DP, Dang, TP. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res, 67(17), 8051-7, 2007. PMCID:2245859

Taguchi, F, Solomon, B, Gregorc, V, Roder, H, Gray, R, Kasahara, K, Nishio, M, Brahmer, J, Spreafico, A, Ludovini, V, Massion, PP, Dziadziuszko, R, Schiller, J, Grigorieva, J, Tsypin, M, Hunsucker, SW, Caprioli, R, Duncan, MW, Hirsch, FR, Bunn, PA, Carbone, DP. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst, 99(11), 838-46, 2007. PMCID:2245859

Yang, L, Amann, JM, Kikuchi, T, Porta, R, Guix, M, Gonzalez, A, Park, KH, Billheimer, D, Arteaga, CL, Tai, HH, DuBois, R, Carbone, DP, Johnson, DH. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res, 67(12), 5587-93, 2007. PMCID:2245859

Yildiz, PB, Shyr, Y, Rahman, JS, Wardwell, NR, Zimmerman, LJ, Shakhtour, B, Gray, WH, Chen, S, Li, M, Roder, H, Liebler, DC, Bigbee, WL, Siegfried, JM, Weissfeld, JL, Gonzalez, AL, Ninan, M, Johnson, DH, Carbone, DP, Caprioli, RM, Massion, PP. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol, 2(10), 893-901, 2007. PMCID:2245859

Acuff, HB, Sinnamon, M, Fingleton, B, Boone, B, Levy, SE, Chen, X, Pozzi, A, Carbone, DP, Schwartz, DR, Moin, K, Sloane, BF, Matrisian, LM. Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res, 66(16), 7968-75, 2006.

Amann, JM, Chaurand, P, Gonzalez, A, Mobley, JA, Massion, PP, Carbone, DP, Caprioli, RM. Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Cancer Res, 12(17), 5142-50, 2006.

Csiki, I, Yanagisawa, K, Haruki, N, Nadaf, S, Morrow, JD, Johnson, DH, Carbone, DP. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res, 66(1), 143-50, 2006.

Yang, L, Huang, Y, Porta, R, Yanagisawa, K, Gonzalez, A, Segi, E, Johnson, DH, Narumiya, S, Carbone, DP. Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis with Selective EP4 Receptor Antagonism. Cancer Res, 66(19), 9665-72, 2006.

Amann, J, Kalyankrishna, S, Massion, PP, Ohm, JE, Girard, L, Shigematsu, H, Peyton, M, Juroske, D, Huang, Y, Stuart Salmon, J, Kim, YH, Pollack, JR, Yanagisawa, K, Gazdar, A, Minna, JD, Kurie, JM, Carbone, DP. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res, 65(1), 226-35, 2005.

Anumanthan, G, Halder, SK, Osada, H, Takahashi, T, Massion, PP, Carbone, DP, Datta, PK. Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells. Br J Cancer, 93(10), 1157-67, 2005. PMCID:2361493

Carbone, DP, Ciernik, IF, Kelley, MJ, Smith, MC, Nadaf, S, Kavanaugh, D, Maher, VE, Stipanov, M, Contois, D, Johnson, BE, Pendleton, CD, Seifert, B, Carter, C, Read, EJ, Greenblatt, J, Top, LE, Kelsey, MI, Minna, JD, Berzofsky, JA. Immunization With Mutant p53- and K-ras-Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome. J Clin Oncol, 23(22), 5099-107, 2005.

Csiki, I, Morrow, JD, Sandler, A, Shyr, Y, Oates, J, Williams, MK, Dang, T, Carbone, DP, Johnson, DH. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res, 11(18), 6634-40, 2005.

Dikov, MM, Ohm, JE, Ray, N, Tchekneva, EE, Burlison, J, Moghanaki, D, Nadaf, S, Carbone, DP. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol, 174(1), 215-22, 2005.

Haruki, N, Kawaguchi, KS, Eichenberger, S, Massion, PP, Gonzalez, A, Gazdar, AF, Minna, JD, Carbone, DP, Dang, TP. Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro. J Med Genet, 42(7), 558-64, 2005. PMCID:1736105

Haruki, N, Kawaguchi, KS, Eichenberger, S, Massion, PP, Olson, S, Gonzalez, A, Carbone, DP, Dang, TP. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res, 65(9), 3555-61, 2005.

Herbst, RS, Johnson, DH, Mininberg, E, Carbone, DP, Henderson, T, Kim, ES, Blumenschein, G, Lee, JJ, Liu, DD, Truong, MT, Hong, WK, Tran, H, Tsao, A, Xie, D, Ramies, DA, Mass, R, Seshagiri, S, Eberhard, DA, Kelley, SK, Sandler, A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol, 23(11), 2544-55, 2005.

Min, Y, Adachi, Y, Yamamoto, H, Imsumran, A, Arimura, Y, Endo, T, Hinoda, Y, Lee, CT, Nadaf, S, Carbone, DP, Imai, K. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut, 54(5), 591-600, 2005. PMCID:1774471

Rahman, SM, Shyr, Y, Yildiz, PB, Gonzalez, AL, Li, H, Zhang, X, Chaurand, P, Yanagisawa, K, Slovis, BS, Miller, RF, Ninan, M, Miller, YE, Franklin, WA, Caprioli, RM, Carbone, DP, Massion, PP. Proteomic patterns of preinvasive bronchial lesions. Am J Respir Crit Care Med, 172(12), 1556-62, 2005. PMCID:2718455

Shinohara, ET, Gonzalez, A, Massion, PP, Chen, H, Li, M, Freyer, AS, Olson, SJ, Andersen, JJ, Shyr, Y, Carbone, DP, Johnson, DH, Hallahan, DE, Lu, B. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer, 103(8), 1685-92, 2005.

Adachi, Y, Lee, CT, Carbone, DP. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy. Novartis Found Symp, 262, 177-89; discussion 190-2, 265-8, 2004.

Carbone, DP. Lung cancer: early events, early interventions: conference summary for the 46th Annual Thomas L Petty Aspen Lung Conference. Chest, 125(5 Suppl), 167S-72S, 2004.

Carbone, DP. Biomarkers of response to gefitinib in non-small-cell lung cancer. Nat Clin Pract Oncol, 1(2), 66-7, 2004.

Lee, CT, Park, KH, Yanagisawa, K, Adachi, Y, Ohm, JE, Nadaf, S, Dikov, MM, Curiel, DT, Carbone, DP. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus. Cancer Res, 64(18), 6660-5, 2004.

Lu, B, Gonzalez, A, Massion, PP, Shyr, Y, Shaktour, B, Carbone, DP, Hallahan, DE. Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer, 91(3), 537-40, 2004. PMCID:2409840

Massion, PP, Taflan, PM, Rahman, SM, Yildiz, P, Shyr, Y, Carbone, DP, Gonzalez, AL. Role of p63 amplification and overexpression in lung cancer development. Chest, 125(5 Suppl), 102S, 2004.

Yang, L, Carbone, DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res, 92, 13-27, 2004.

Yang, L, DeBusk, LM, Fukuda, K, Fingleton, B, Green-Jarvis, B, Shyr, Y, Matrisian, LM, Carbone, DP, Lin, PC. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6(4), 409-21, 2004.

Carbone, DP. Epidermal growth factor receptor overexpression: the importance of context. J Clin Oncol, 21(23), 4268-9, 2003.

Dang, Thao P, Eichenberger, Shannon, Gonzalez, Adriana, Olson, Sandra, Carbone, David P. Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. Oncogene, 22(13), 1988-97, 2003.

Franklin, WA, Carbone, DP. Molecular staging and pharmacogenomics. Clinical implications: from lab to patients and back. Lung Cancer, 41 Suppl 1, S147-54, 2003.

Hege, KM, Carbone, DP. Lung cancer vaccines and gene therapy. Lung Cancer, 41 Suppl 1, S103-13, 2003.

Herbst, RS, Hammond, LA, Carbone, DP, Tran, HT, Holroyd, KJ, Desai, A, Williams, JI, Bekele, BN, Hait, H, Allgood, V, Solomon, S, Schiller, JH. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res, 9(11), 4108-15, 2003.

Lee, Choon-Taek, Park, Kyung-Ho, Adachi, Yasushi, Seol, Ja Young, Yoo, Chul-Gyu, Kim, Young Whan, Han, Sung Koo, Shim, Young-Soo, Coffee, Keith, Dikov, Mikhail M, Carbone, David P. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther, 10(1), 57-63, 2003.

Massion, Pierre P, Carbone, David P. From clinical and pathologic to molecular staging of lung cancer. Am J Respir Crit Care Med, 167(12), 1587-8, 2003.

Massion, Pierre P, Carbone, David P. The molecular basis of lung cancer: molecular abnormalities and therapeutic implications. Respir Res, 4(1), 12, 2003. PMCID:314397

Massion, Pierre P, Taflan, Peter M, Jamshedur Rahman, S M, Yildiz, Pinar, Shyr, Yu, Edgerton, Mary E, Westfall, Matthew D, Roberts, John R, Pietenpol, Jennifer A, Carbone, David P, Gonzalez, Adriana L. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res, 63(21), 7113-21, 2003.

Min, Y, Adachi, Y, Yamamoto, H, Ito, H, Itoh, F, Lee, CT, Nadaf, S, Carbone, DP, Imai, K. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res, 63(19), 6432-41, 2003.

Ohm, Joyce E, Gabrilovich, Dmitry I, Sempowski, Gregory D, Kisseleva, Ekaterina, Parman, Kelly S, Nadaf, Sorena, Carbone, David P. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood, 101(12), 4878-86, 2003.

Rothenberg, Mace L, Carbone, David P, Johnson, David H. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer, 3(4), 303-9, 2003.

Yamagata, Noboru, Shyr, Yu, Yanagisawa, Kiyoshi, Edgerton, Mary, Dang, Thao P, Gonzalez, Adriana, Nadaf, Sorena, Larsen, Paul, Roberts, John R, Nesbitt, Jonathan C, Jensen, Roy, Levy, Shawn, Moore, Jason H, Minna, John D, Carbone, David P. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res, 9(13), 4695-704, 2003.

Yanagisawa, Kiyoshi, Shyr, Yu, Xu, Baogang J, Massion, Pierre P, Larsen, Paul H, White, Bill C, Roberts, John R, Edgerton, Mary, Gonzalez, Adriana, Nadaf, Sorena, Moore, Jason H, Caprioli, Richard M, Carbone, David P. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet, 362(9382), 433-9, 2003.

Yanagisawa, Kiyoshi, Xu, Baogang J, Carbone, David P, Caprioli, Richard M. Molecular fingerprinting in human lung cancer. Clin Lung Cancer, 5(2), 113-8, 2003.

Yang, Li, Yamagata, Noboru, Yadav, Rajwardhan, Brandon, Suzanne, Courtney, Regina L, Morrow, Jason D, Shyr, Yu, Boothby, Mark, Joyce, Sebastian, Carbone, David P, Breyer, Richard M. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest, 111(5), 727-35, 2003. PMCID:151895

Adachi, Yasushi, Lee, Choon-Taek, Coffee, Keith, Yamagata, Noboru, Ohm, Joyce E, Park, Kyung-Ho, Dikov, Mikhail M, Nadaf, Sorena R, Arteaga, Carlos L, Carbone, David P. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology, 123(4), 1191-204, 2002.

Gabrilovich, Dmitry I, Cheng, Pingyan, Fan, Yuhong, Yu, Bin, Nikitina, Ekaterina, Sirotkin, Allen, Shurin, Michael, Oyama, Tsunehiro, Adachi, Yasushi, Nadaf, Sorena, Carbone, David P, Skoultchi, Arthur I. H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factors. J Leukoc Biol, 72(2), 285-96, 2002.

Ohm, JE, Carbone, DP. Immune dysfunction in cancer patients. Oncology (Williston Park), 16(1 Suppl 1), 11-8, 2002.

Swisher, Stephen G, Roth, Jack A, Carbone, David P. Genetic and immunologic therapies for lung cancer. Semin Oncol, 29(1 Suppl 4), 95-101, 2002.

Adachi, Y, Itoh, F, Yamamoto, H, Arimura, Y, Kikkawa-Okabe, Y, Miyazaki, K, Carbone, D P, Imai, K. Expression of angiomodulin (tumor-derived adhesion factor/mac25) in invading tumor cells correlates with poor prognosis in human colorectal cancer. Int J Cancer, 95(4), 216-22, 2001.

Almand, B, Carbone, D P. Biological considerations in lung cancer. Cancer Treat Res, 105, 1-30, 2001.

Almand, B, Clark, J I, Nikitina, E, van Beynen, J, English, N R, Knight, S C, Carbone, D P, Gabrilovich, D I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol, 166(1), 678-89, 2001.

Asai, K, Kitaura, J, Kawakami, Y, Yamagata, N, Tsai, M, Carbone, D P, Liu, F T, Galli, S J, Kawakami, T. Regulation of mast cell survival by IgE. Immunity, 14(6), 791-800, 2001.

Dikov, M M, Oyama, T, Cheng, P, Takahashi, T, Takahashi, K, Sepetavec, T, Edwards, B, Adachi, Y, Nadaf, S, Daniel, T, Gabrilovich, D I, Carbone, D P. Vascular endothelial growth factor effects on nuclear factor-kappaB activation in hematopoietic progenitor cells. Cancer Res, 61(5), 2015-21, 2001.

Jagasia, M H, Langer, C J, Johnson, D H, Yunus, F, Rodgers, J S, Schlabach, L L, Cohen, A G, Shyr, Y, Carbone, D P, Devore, R F. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin Cancer Res, 7(1), 68-73, 2001.

Nikitina, E Y, Clark, J I, Van Beynen, J, Chada, S, Virmani, A K, Carbone, D P, Gabrilovich, D I. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res, 7(1), 127-35, 2001.

Ohm, J E, Carbone, D P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res, 23(2-3), 263-72, 2001.

Rosenthal, D I, Lee, J H, Sinard, R, Yardley, D A, Machtay, M, Rosen, D M, Egorin, M J, Weber, R S, Weinstein, G S, Chalian, A A, Miller, L K, Frenkel, E P, Carbone, D P. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol, 19(5), 1363-73, 2001.

Almand, B, Resser, J R, Lindman, B, Nadaf, S, Clark, J I, Kwon, E D, Carbone, D P, Gabrilovich, D I. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res, 6(5), 1755-66, 2000.

Dang, T P, Gazdar, A F, Virmani, A K, Sepetavec, T, Hande, K R, Minna, J D, Roberts, J R, Carbone, D P. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst, 92(16), 1355-7, 2000.

Rosenthal, D I, Becerra, C R, Toto, R D, Carbone, D P, Frenkel, E P. Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrin. Am J Clin Oncol, 23(6), 593-8, 2000.

Terabe, M, Matsui, S, Noben-Trauth, N, Chen, H, Watson, C, Donaldson, D D, Carbone, D P, Paul, W E, Berzofsky, J A. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol, 1(6), 515-20, 2000.

Amorino, G P, Freeman, M L, Carbone, D P, Lebwohl, D E, Choy, H. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Int J Radiat Oncol Biol Phys, 44(2), 399-405, 1999.

Carbone, D P. Molecular modalities in the treatment of lung cancer. Oncology (Huntingt), 13(10 Suppl 5), 142-7, 1999.

Ciernik, I F, Romero, P, Berzofsky, J A, Carbone, D P. Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope. Int J Radiat Oncol Biol Phys, 45(3), 735-41, 1999.

Dowell, J E, Sinard, R, Yardley, D A, Aviles, V, Machtay, M, Weber, R S, Weinstein, G S, Chalian, A A, Carbone, D P, Rosenthal, D I. Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Semin Radiat Oncol, 9(2 Suppl 1), 97-101, 1999.

Gabrilovich, D I, Ishida, T, Nadaf, S, Ohm, J E, Carbone, D P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res, 5(10), 2963-70, 1999.

Ishida, T, Chada, S, Stipanov, M, Nadaf, S, Ciernik, F I, Gabrilovich, D I, Carbone, D P. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol, 117(2), 244-51, 1999. PMCID:1905349

Ishida, T, Hinoda, Y, Carbone, D P, Imai, K. [Gene-immunotherapy using dendritic cells]. Nihon Rinsho Meneki Gakkai Kaishi, 22(6), 448-51, 1999.

Johnson, D H, Carbone, D P. Increased dose-intensity in small-cell lung cancer: a failed strategy?. J Clin Oncol, 17(8), 2297-9, 1999.

Matsui, S, Ahlers, J D, Vortmeyer, A O, Terabe, M, Tsukui, T, Carbone, D P, Liotta, L A, Berzofsky, J A. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol, 163(1), 184-93, 1999.

Ohm, J E, Shurin, M R, Esche, C, Lotze, M T, Carbone, D P, Gabrilovich, D I. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol, 163(6), 3260-8, 1999.

Rosenthal, D I, Nurenberg, P, Becerra, C R, Frenkel, E P, Carbone, D P, Lum, B L, Miller, R, Engel, J, Young, S, Miles, D, Renschler, M F. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res, 5(4), 739-45, 1999.

Wu, C W, Lin, Y Y, Chen, G D, Chi, C W, Carbone, D P, Chen, J Y. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer, 80(3-4), 483-8, 1999. PMCID:2362310

Gabrilovich, D, Ishida, T, Oyama, T, Ran, S, Kravtsov, V, Nadaf, S, Carbone, D P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 92(11), 4150-66, 1998.

Ishida, T, Oyama, T, Carbone, D P, Gabrilovich, D I. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol, 161(9), 4842-51, 1998.

Lee, J H, Lee, C T, Yoo, C G, Hong, Y K, Kim, C M, Han, S K, Shim, Y S, Carbone, D P, Kim, Y W. The inhibitory effect of adenovirus-mediated p16INK4a gene transfer on the proliferation of lung cancer cell line. Anticancer Res, 18(5A), 3257-61, 1998.

Oyama, T, Ran, S, Ishida, T, Nadaf, S, Kerr, L, Carbone, D P, Gabrilovich, D I. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol, 160(3), 1224-32, 1998.

Resser, J R, Carbone, D P. Immunotherapy of head and neck cancer. Curr Opin Oncol, 10(3), 226-32, 1998.

Carbone, D P. The biology of lung cancer. Semin Oncol, 24(4), 388-401, 1997.

Chen, H L, Carbone, D P. p53 as a target for anti-cancer immunotherapy. Mol Med Today, 3(4), 160-7, 1997.

Gabrilovich, D I, Corak, J, Ciernik, I F, Kavanaugh, D, Carbone, D P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res, 3(3), 483-90, 1997.

Gabrilovich, D. I., Cunningham, H. T. and Carbone, D. P. IL-12 and mutant p53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. Journal of Immunotherapy, 19, 414-418, 1997.

Lee, C T, Wu, S, Ciernik, I F, Chen, H, Nadaf-Rahrov, S, Gabrilovich, D, Carbone, D P. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther, 8(2), 187-93, 1997.

Rosenthal, D I, Okani, O, Corak, J, Kavanaugh, D, Kamen, B, Vuitch, F M, Gazdar, A F, Greiner, J, Frenkel, E F, Carbone, D P. Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study. Semin Oncol, 24(4 Suppl 12), S12-96-S12-100, 1997.

Rosenthal, D I, Okani, O, Truelson, J M, Fathallah-Shaykh, H, Vuitch, F M, Gazdar, A F, Griener, J, Landay, M, Mendelsohn, D, Tourville, J, Hamilton, L, Orr, K Y, McWhorter, J, Carbone, D P. Intensive radiation therapy concurrent with up to 7-week continuous-infusion paclitaxel for locally advanced solid tumors: phase I studies. Semin Oncol, 24(1 Suppl 2), S2-81-S2-84, 1997.

Rosenthal, D I, Sinard, R J, Okani, O, Corak, J, Kavanaugh, D, Kamen, B, Vuitch, F M, Gazdar, A F, Griener, J, Frenkel, E P, Carbone, D P. Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: a phase I study. Semin Oncol, 24(6 Suppl 19), S19-67-S19-71, 1997.

Smith, M C, Pendleton, C D, Maher, V E, Kelley, M J, Carbone, D P, Berzofsky, J A. Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing. Int Immunol, 9(8), 1085-93, 1997.

Tang, D C, Jennelle, R S, Shi, Z, Garver, R I, Carbone, D P, Loya, F, Chang, C H, Curiel, D T. Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells. Hum Gene Ther, 8(17), 2117-24, 1997.

Chen, H L, Gabrilovich, D, Tamp??, R, Girgis, K R, Nadaf, S, Carbone, D P. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet, 13(2), 210-3, 1996.

Chen, H. L., Gabrilovich, D., Virmani, A., Ratnani, I., Girgis, K. R., Nadaf-Rahrov, S., Fernandez-Vina, M. and Carbone, D. P. Structural and functional analysis of B2 microglobulin abnormalities in human lung and breast cancer. International Journal of Cancer, 67, 756-763, 1996.

Chen, HL, Gabrilovich, D, Virmani, A, Ratnani, I, Girgis, KR, Nadaf-Rahrov, S, Fernandez-Vi??a, M, Carbone, DP. Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer. Int J Cancer, 67(6), 756-63, 1996.

Ciernik, I F, Berzofsky, J A, Carbone, D P. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol, 156(7), 2369-75, 1996.

Ciernik, I F, Berzofsky, J A, Carbone, D P. Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes. Clin Cancer Res, 2(5), 877-82, 1996.

Ciernik, I F, Krayenb??hl, B H, Carbone, D P. Puncture-mediated gene transfer to the skin. Hum Gene Ther, 7(8), 893-9, 1996.

D. I. Gabrilovich, I. F. Ciernik, D. P. Carbone. Dendritic Cells In Anti-Tumor Immune Responses. I. Defective Antigen Presentation In Tumor-Bearing Hosts. Cellular Immunology, 170, 101-110, 1996.

D. I. Gabrilovich, S. Nadaf, J. Corak, J. A. Berzofsky, and D. P. Carbone. Dendritic Cells In Anti-Tumor Immune Responses. Ii. Dendritic Cells Grown From Bone Marrow Precursors, But Not Mature DC From Tumor-Bearing Mice Are Effective Antigen Carriers In The Therapy Of Established Tumors. Cellular Immunology, 170, 111-119, 1996.

Gabrilovich, D I, Chen, H L, Girgis, K R, Cunningham, H T, Meny, G M, Nadaf, S, Kavanaugh, D, Carbone, D P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med, 2(10), 1096-103, 1996.

Gabrilovich, D I, Ciernik, I F, Carbone, D P. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol, 170(1), 101-10, 1996.

Gabrilovich, D I, Cunningham, H T, Carbone, D P. IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. J Immunother Emphasis Tumor Immunol, 19(6), 414-8, 1996.

Gabrilovich, D I, Nadaf, S, Corak, J, Berzofsky, J A, Carbone, D P. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol, 170(1), 111-9, 1996.

Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, T., Meny, G. M., Nadaf, S., Kavanaugh, D. and Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Medicine, 205, 1096-1103, 1996.

Kavanaugh, D Y, Carbone, D P. Immunologic dysfunction in cancer. Hematol Oncol Clin North Am, 10(4), 927-51, 1996.

Lee, C T, Ciernik, I F, Wu, S, Tang, D C, Chen, H L, Truelson, J M, Carbone, D P. Increased immunogenicity of tumors bearing mutant p53 and P1A epitopes after transduction of B7-1 via recombinant adenovirus. Cancer Gene Ther, 3(4), 238-44, 1996.

Lee, C T, Wu, S, Gabrilovich, D, Chen, H, Nadaf-Rahrov, S, Ciernik, I F, Carbone, D P. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res, 56(13), 3038-41, 1996.

Phelps, R M, Johnson, B E, Ihde, D C, Gazdar, A F, Carbone, D P, McClintock, P R, Linnoila, R I, Matthews, M J, Bunn, P A, Carney, D, Minna, J D, Mulshine, J L. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl, 24, 32-91, 1996.

Tang, D C, Gazdar, A F, Carbone, D P. In vivo cytotoxicity assay for assessing immunity. J Immunol Methods, 189(2), 173-82, 1996.

Tsukui, T, Hildesheim, A, Schiffman, M H, Lucci, J, Contois, D, Lawler, P, Rush, B B, Lorincz, A T, Corrigan, A, Burk, R D, Qu, W, Marshall, M A, Mann, D, Carrington, M, Clerici, M, Shearer, G M, Carbone, D P, Scott, D R, Houghten, R A, Berzofsky, J A. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res, 56(17), 3967-74, 1996.

Carbone, D P, Minna, J D. Chemotherapy for non-small cell lung cancer. BMJ, 311(7010), 889-90, 1995. PMCID:2550912

Ciernik, I F, Berzofsky, J, Carbone, D P. Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. Hybridoma, 14(2), 139-42, 1995.

Ciernik, I F, Krayenb??hl Ciernik, B H, Cockerell, C J, Minna, J D, Gazdar, A F, Carbone, D P. Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi's sarcoma. Clin Cancer Res, 1(10), 1119-24, 1995.

Ciernik, I., Berzofsky, J., and Carbone, D.P. Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. Hybridoma, 14, 139-142, 1995.

Lee, C T, Chen, H L, Carbone, D P. Gene therapy for lung cancer. Ann Oncol, 6 Suppl 3, S61-3, 1995.

Rosenthal, D I, Carbone, D P. Taxol plus radiation for head and neck cancer. J Infus Chemother, 5(2), 46-54, 1995.

Santoso, J T, Tang, D C, Lane, S B, Hung, J, Reed, D J, Muller, C Y, Carbone, D P, Lucci, J A, Miller, D S, Mathis, J M. Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol, 59(2), 171-8, 1995.

Carbone, D P, Minna, J D. In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirus. J Natl Cancer Inst, 86(19), 1437-8, 1994.

Carbone, D P, Mitsudomi, T, Chiba, I, Piantadosi, S, Rusch, V, Nowak, J A, McIntire, D, Slamon, D, Gazdar, A, Minna, J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest, 106(6 Suppl), 377S-381S, 1994.

Gazdar, A F, Bader, S, Hung, J, Kishimoto, Y, Sekido, Y, Sugio, K, Virmani, A, Fleming, J, Carbone, D P, Minna, J D. Molecular genetic changes found in human lung cancer and its precursor lesions. Cold Spring Harb Symp Quant Biol, 59, 565-72, 1994.

Sekido, Y, Bader, S A, Carbone, D P, Johnson, B E, Minna, J D. Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines. Cancer Res, 54(18), 4988-92, 1994.

Tang, D C, Johnston, S A, Carbone, D P. Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. Cancer Gene Ther, 1(1), 15-20, 1994.

Tang, D.-C, Johnston, S.A. and Carbone, D.P. Tumor-restricted gene expression by adenovirus-mediated gene transfer. Cancer Gene Therapy , 1, 15-20, 1994.

Wiedenfeld, E A, Fernandez-Vi??a, M, Berzofsky, J A, Carbone, D P. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. Cancer Res, 54(5), 1175-7, 1994.

Carbone, D P. Oncogenes and tumor suppressor genes. Hosp Pract (Off Ed), 28(6), 145-8, 153-6, 161, 1993.

Carbone, D P, Minna, J D. Antioncogenes and human cancer. Annu Rev Med, 44, 451-64, 1993.

Kim, J H, Choi, J J, Noh, S H, Roh, J K, Min, J S, Youn, J K, Yoo, N C, Lim, H Y, Carbone, D P, Gazdar, A F. Comparison of p53 gene mutations in paired primary and metastatic gastric tumor tissues. J Korean Med Sci, 8(3), 187-91, 1993.

Tang, D C, Carbone, D P. Potential application of gene therapy to lung cancer. Semin Oncol, 20(4), 368-73, 1993.

Winter, S F, Sekido, Y, Minna, J D, McIntire, D, Johnson, B E, Gazdar, A F, Carbone, D P. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst, 85(24), 2012-8, 1993.

Yanuck, M, Carbone, D P, Pendleton, C D, Tsukui, T, Winter, S F, Minna, J D, Berzofsky, J A. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res, 53(14), 3257-61, 1993.

Bodner, S.M., Minna, J., Jensen, S.M., D'Amico, D., Carbone, D., Mitsudomi, T., Fedorko, J., Nau, M., Gazdar, A.F., and Linnoila, R.I. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7, 743-749, 1992.

Carbone, D P, Minna, J D. The molecular genetics of lung cancer. Adv Intern Med, 37, 153-71, 1992.

D'Amico, D, Carbone, D P, Johnson, B E, Meltzer, S J, Minna, J D. Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer. Cancer Res, 52(7), 1996-9, 1992.

D'Amico, D., Carbone, D., Mitsudomi, T., Nau, M., Fedorko, J., Russell, E., Johnson, B., Buchhagen, D., Bodner, S., Phelps, R., Gazdar, A.F., and Minna, J.D. High frequency of somatically acquired p53 mutations in small cell lung cancer cell lines and tumors. Oncogene, 7, 339-346, 1992.

Mitsudomi, T., Stinberg, S.M., Nau M., Carbone, D., D'Amico, D., Bodner, S., Oie, H.K., Linnoila, R.I., Mulshine, J.L., Minna, J.D., and Gazdar, A.F. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene , 7, 171-180, 1992.

Takahashi, T., Carbone, D., Takahashi, T., Nau, M., Hida, T., Linnoila, I., Ueda, R., and Minna, J.D. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Research, 53, 2340-2343, 1992.

Winter, S F, Minna, J D, Johnson, B E, Takahashi, T, Gazdar, A F, Carbone, D P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res, 52(15), 4168-74, 1992.

Carbone, D P, Koros, A M, Linnoila, R I, Jewett, P, Gazdar, A F. Neural cell adhesion molecule expression and messenger RNA splicing patterns in lung cancer cell lines are correlated with neuroendocrine phenotype and growth morphology. Cancer Res, 51(22), 6142-9, 1991.

Carbone, D., Chiba, I., and Mitsudoma, T. Polymorphism at codon 213 within p53. Oncogene, 6, 1691-1692, 1991.

McDaniel, T., Carbone, D., Takahashi, T., Chumakov, P., Chang, E.H., Pirollo, K.F., Yin, J., Huang, Y., and Meltzer, S.J. The MspI polymorphisn in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Research, 19, 4796, 1991.

Mason, P W, Carbone, D P, Cushman, R A, Waggoner, A S. The importance of inorganic phosphate in regulation of energy metabolism of Streptococcus lactis. J Biol Chem, 256(4), 1861-6, 1981.

Ergun, D L, Mistretta, C A, Kruger, R A, Riederer, S J, Shaw, C G, Carbone, D P. A hybrid computerized fluoroscopy technique for noninvasive cardiovascular imaging. Radiology, 132(3), 739-42, 1979.

Postdoctoral Position Available

Postdoctoral Position Details
Vanderbilt-Ingram Cancer Center. NIH-supported post-doctoral position available immediately to study molecular genetics and proteomics in lung cancers. A Ph.D. with strong background in cell biology, molecular biology or genetics is preferred. Please send curriculum vitae and names of three references to:

David P. Carbone, M.D., Ph.D.
Professor of Medicine and Cancer Biology
Vanderbilt-Ingram Cancer Center
648 Preston Research Building
Nashville, TN 37232

or fax CV to:
(615) 936-3322

Updated Date

Vanderbilt University is committed to principles of equal opportunity and affirmative action.
Copyright 2008 Vanderbilt University School of Medicine
The office of Biomedical Research Education & Training All rights reserved.
For questions or problems concerning this page, please submit a help ticket.